A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
暂无分享,去创建一个
W. M. Smit | H. Hollema | F. Erdkamp | A. Reyners | M. Schaapveld | L. de Munck | K. Hoekman | P. Willemse | A. Wymenga | H. de Graaf | M. van Vugt | R. Lalisang | M. Polee